Jennifer Moritz1, Thomas Bauernhofer1, Sebastian Mannweiler2, Tanja Langsenlehner3, Karl Pummer4, Nadia Dandachi5,6, Martin Pichler5. 1. Division of Oncology, Department of Internal Medicine, Medical University of Graz (MUG), Graz, Austria. 2. Department of Pathology, Medical University of Graz, Graz, Austria. 3. Department of Therapeutic Radiology and Oncology, Medical University of Graz, Graz, Austria. 4. Department of Urology, Medical University of Graz, Graz, Austria. 5. Division of Oncology, Department of Internal Medicine, Medical University of Graz (MUG), Graz, Austria Nadia.dandachi@medunigraz.at martin.pichler@medunigraz.at. 6. Research Unit Epigenetic and Genetic Cancer Biomarkers, Medical University of Graz, Graz, Austria.
Abstract
BACKGROUND/AIM: Carboplatin-containing treatment regimens demonstrate moderate efficacy in metastatic castration-resistant prostate cancer (mCRPC). In this study, we retrospectively analyzed the efficacy of carboplatin in relation to blood-based parameters. PATIENTS AND METHODS: A retrospective chart review was performed for 20 patients with mCRPC who received carboplatin in a single center. RESULTS: Median overall survival was 3.8 months (95%CI=1.5-7.1), median progression-free survival was 1.7 months. We observed two partial remissions (PR, 10%), four stable diseases (SD, 20%) and 14 disease progressions (PD, 70%), resulting in a clinical benefit rate of 30%. A doubling of NSE (neurone specific enolase) values was associated with a 19% absolute higher response rate (95%CI=14-23, p=0.027). All other laboratory parameters failed as predictive markers of response to carboplatin. In univariate Cox regression analysis, only NSE was significantly associated with impaired PFS (HR=0.7, 95%CI=0.56-0.96, p=0.030). CONCLUSION: Carboplatin showed moderate efficacy against mCRPC in this unselected population of patients and NSE levels may help to predict the success of this treatment. Copyright
BACKGROUND/AIM: Carboplatin-containing treatment regimens demonstrate moderate efficacy in metastatic castration-resistant prostate cancer (mCRPC). In this study, we retrospectively analyzed the efficacy of carboplatin in relation to blood-based parameters. PATIENTS AND METHODS: A retrospective chart review was performed for 20 patients with mCRPC who received carboplatin in a single center. RESULTS: Median overall survival was 3.8 months (95%CI=1.5-7.1), median progression-free survival was 1.7 months. We observed two partial remissions (PR, 10%), four stable diseases (SD, 20%) and 14 disease progressions (PD, 70%), resulting in a clinical benefit rate of 30%. A doubling of NSE (neurone specific enolase) values was associated with a 19% absolute higher response rate (95%CI=14-23, p=0.027). All other laboratory parameters failed as predictive markers of response to carboplatin. In univariate Cox regression analysis, only NSE was significantly associated with impaired PFS (HR=0.7, 95%CI=0.56-0.96, p=0.030). CONCLUSION: Carboplatin showed moderate efficacy against mCRPC in this unselected population of patients and NSE levels may help to predict the success of this treatment. Copyright
Authors: Michael S Humeniuk; Rajan T Gupta; Patrick Healy; Megan McNamara; Sundhar Ramalingam; Michael Harrison; Daniel George; Tian Zhang; Yuan Wu; Andrew J Armstrong Journal: Prostate Cancer Prostatic Dis Date: 2017-12-11 Impact factor: 5.554
Authors: Esther W Bouman-Wammes; H Pieter van den Berg; Linda de Munck; Aart Beeker; Carolien H Smorenburg; Walter L Vervenne; Juleon L L M Coenen; Henk M W Verheul; Winald R Gerritsen; Alfons J M Van den Eertwegh Journal: Eur J Cancer Date: 2017-12-18 Impact factor: 9.162
Authors: Carlo Buonerba; Piera Federico; Davide Bosso; Livio Puglia; Tania Policastro; Michela Izzo; Francesco Perri; Giuseppina Della Vittoria Scarpati; Matteo Ferro; Ottavio De Cobelli; Sabino De Placido; Michele Aieta; Ciro Imbimbo; Nicola Longo; Giuseppe Di Lorenzo Journal: Future Oncol Date: 2014-06 Impact factor: 3.404
Authors: Rosa Nadal; Michael Schweizer; Oleksandr N Kryvenko; Jonathan I Epstein; Mario A Eisenberger Journal: Nat Rev Urol Date: 2014-02-18 Impact factor: 14.432
Authors: Ana M Aparicio; Andrea L Harzstark; Paul G Corn; Sijin Wen; John C Araujo; Shi-Ming Tu; Lance C Pagliaro; Jeri Kim; Randall E Millikan; Charles Ryan; Nizar M Tannir; Amado J Zurita; Paul Mathew; Wadih Arap; Patricia Troncoso; Peter F Thall; Christopher J Logothetis Journal: Clin Cancer Res Date: 2013-05-06 Impact factor: 12.531